1
|
Liu C, Nakano-Tateno T, Satou M, Chik C, Tateno T. Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas. Endocr J 2021; 68:1143-1153. [PMID: 34248112 DOI: 10.1507/endocrj.ej21-0106] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Pituitary adenomas are benign tumours that can cause an individual various clinical manifestations including tumour mass effects and/or the diverse effects of abnormal pituitary hormone secretion. Given the morbidity and limited treatment options for pituitary adenomas, there is a need for better biomarkers and treatment options. One molecule that is of specific interest is the signal transducer and activator of transcription 3 (STAT3), a transcription factor that plays a critical role in mediating cytokine-induced changes in gene expression. In addition, STAT3 controls cell proliferation by regulating mitochondrial activity. Not only does activation of STAT3 play a crucial role in tumorigenesis, including pituitary tumorigenesis, but a number of studies also demonstrate pharmacological STAT3 inhibition as a promising treatment approach for many types of tumours, including pituitary tumours. This review will focus on the role of STAT3 in different pituitary adenomas, in particular, growth hormone-producing adenomas and null cell adenomas. Furthermore, how STAT3 is involved in the cell proliferation and hormone regulation in pituitary adenomas and its potential role as a molecular therapeutic target in pituitary adenomas will be summarized.
Collapse
Affiliation(s)
- Cyndy Liu
- Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Tae Nakano-Tateno
- Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Motoyasu Satou
- Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
- Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan
| | - Constance Chik
- Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Toru Tateno
- Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
2
|
You H, Xu J, Qin X, Qian G, Wang Y, Chen F, Shen X, Zhao D, Liu Q. Fascin promotes the invasion of pituitary adenoma through partial dependence on epithelial-mesenchymal transition. J Mol Histol 2021; 52:823-838. [PMID: 34097178 DOI: 10.1007/s10735-021-09995-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 06/03/2021] [Indexed: 11/30/2022]
Abstract
The aim of the present study was to investigate the role and potential regulatory mechanisms of fascin in the invasion and epithelial-to-mesenchymal transition of pituitary adenoma cells. A total of 30 specimens were assessed in the present study. The expression levels of fascin in the invasive pituitary adenoma group and non-invasive pituitary adenoma group were determined by immunochemistry. Fascin was downregulated via small interfering RNA in mouse pituitary AtT-20 cells. The proliferation, cell cycle and apoptosis of AtT-20 cells were assessed using Cell Counting Kit‑8 and flow cytometry. The invasion of AtT-20 cells was detected using a Transwell assay. Transmission electron microscopy was utilized to observe the ultrastructure of AtT-20 cells. Real-time quantitative PCR, Western blotting and immunofluorescence staining were utilized to detect the expression levels of fascin and EMT markers. In the present study, fascin expression and clinical characteristics were not significantly correlated in pituitary adenoma. The protein expression level of fascin in invasive pituitary adenoma was higher than that in non-invasive pituitary adenoma, as assessed by immunochemistry. Downregulation of fascin resulted in significant decreases in cell viability, proliferation and invasion, arrested the cell cycle at the G1 phase and increased apoptosis. In addition, downregulation of fascin significantly decreased the expression levels of N-cadherin, the mesenchymal cell marker vimentin and the transcription factor Twist but significantly increased the expression levels of the epithelial cell marker E-cadherin. Further experiments revealed that overexpression of E-cadherin resulted in significant decreases in cell viability, proliferation, invasion, and the expression of fascin and transcription factor Twist and also arrested the cell cycle at the G2 phase. The results of the present study suggest that suppressing the expression level of fascin could regulate the invasion, proliferation and apoptosis of pituitary tumour cells and alter the expression level of various EMT markers. The present study identified that fascin effectively promotes the invasion, proliferation and apoptosis of pituitary tumour cells partially via the EMT pathway.
Collapse
Affiliation(s)
- Hong You
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Jian Xu
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Xiaochun Qin
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Guodong Qian
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Yang Wang
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Fulei Chen
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Xiaoxu Shen
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Dong Zhao
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China
| | - Qi Liu
- Department of Neurosurgery, The First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, 832000, Xinjiang, China.
| |
Collapse
|